NASDAQ:EOLS - Evolus Stock Price, Forecast & News

Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EOLS shares have decreased by 31.6% and is now trading at $4.04. View which stocks have been mosted impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evolus.

Evolus is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Evolus.

Evolus Inc (NASDAQ:EOLS) announced its quarterly earnings data on Tuesday, February, 25th. The company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.85) by $0.38. The business earned $19.45 million during the quarter, compared to analysts' expectations of $18.93 million. View Evolus' earnings history.

Evolus updated its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $34-35 million, compared to the consensus revenue estimate of $31.8 million.

8 Wall Street analysts have issued 12-month price objectives for Evolus' shares. Their forecasts range from $9.00 to $35.00. On average, they anticipate Evolus' stock price to reach $23.00 in the next year. This suggests a possible upside of 469.3% from the stock's current price. View analysts' price targets for Evolus.

Media coverage about EOLS stock has trended very negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Evolus earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutEvolus.

Evolus saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 7,088,100 shares, a drop of 17.1% from the February 27th total of 8,550,000 shares. Based on an average daily volume of 941,400 shares, the short-interest ratio is presently 7.5 days. Currently, 31.7% of the company's shares are short sold. View Evolus' Current Options Chain.

Some companies that are related to Evolus include ZIOPHARM Oncology (ZIOP), Clovis Oncology (CLVS), Vanda Pharmaceuticals (VNDA), INDIVIOR PLC/S (INVVY), BioXcel Therapeutics (BTAI), Emisphere Technologies (EMIS), Assembly Biosciences (ASMB), ANI Pharmaceuticals (ANIP), Akero Therapeutics (AKRO), Sinovac Biotech (SVA), DiaMedica Therapeutics (DMCAF), Atreca (BCEL), AC Immune (ACIU), Kura Oncology (KURA) and Morphic (MORF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Advanced Micro Devices (AMD), Revance Therapeutics (RVNC), Camtek (CAMT), Plug Power (PLUG), Micron Technology (MU), Canopy Growth (CGC), Calithera Biosciences (CALA), Tandem Diabetes Care (TNDM) and JD.Com (JD).

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Evolus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Tang Capital Management LLC (7.88%), EcoR1 Capital LLC (1.80%), Cadian Capital Management LP (1.52%), Goldman Sachs Group Inc. (1.44%), State Street Corp (0.89%) and Geode Capital Management LLC (0.87%). Company insiders that own Evolus stock include Bosun Hau, Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Michael M Jafar, Rui Avelar, Simone Blank and Vikram Malik. View institutional ownership trends for Evolus.

EOLS stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Raymond James Financial Services Advisors Inc., Bank of America Corp DE, B. Riley Wealth Management Inc., Advisor Group Inc., Victory Capital Management Inc., Victory Capital Management Inc., and Janney Montgomery Scott LLC. Company insiders that have sold Evolus company stock in the last year include Corp Alphaeon, Lauren P Silvernail, and Rui Avelar. View insider buying and selling activity for Evolus.

EOLS stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, EcoR1 Capital LLC, Goldman Sachs Group Inc., Point72 Asset Management L.P., Cadian Capital Management LP, Voss Capital LLC, State Street Corp, and Geode Capital Management LLC. Company insiders that have bought Evolus stock in the last two years include Bosun Hau, David N Gill, Kristine Romine, Michael M Jafar, Simone Blank, and Vikram Malik. View insider buying and selling activity for Evolus.

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EOLS stock can currently be purchased for approximately $4.04.

Evolus has a market capitalization of $136.26 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 70 workers across the globe. View additional information about Evolus.

The official website for Evolus is http://www.evolus.com/.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]